Airway remodeling encompasses the structural alterations in asthmatic compared with
normal airways. Airway remodeling in asthmatic patients involves a wide array of …

Current asthma therapy is based on the use of adrenergic bronchodilator and anti-
inflammatory drugs the specificity, efficacy, duration of action, and safety of which have been …

The chronic inflammatory response within the airways of asthmatics is associated with
structural changes termed airway remodeling. This remodeling process is a key feature of …

Omalizumab is a biological engineered molecule, targeting the Cε3 domain of the IgE
molecule. It binds with free IgE and prevents free IgE from attaching to high-affinity IgE …

Omalizumab is a humanized, monoclonal anti-IgE antibody that binds specifically to
circulating IgE molecules, thus interrupting the allergic cascade. Omalizumab has been …

Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the
treatment of severe allergic asthma. This drug inhibits allergic responses by binding to …

Adult bronchial asthma (hereinafter, asthma) is characterized by chronic airway
inflammation, reversible airway narrowing, and airway hyperresponsiveness. Long-standing …

Mast cells are essential in allergic responses and beyond. White adipose tissue from obese
humans contains large numbers of mast cells. Serum mast cell tryptase levels are also …

To cite this article: Rabe KF, Calhoun WJ, Smith N, Jimenez P. Can anti‐IgE therapy prevent
airway remodeling in allergic asthma? Allergy 2011; 66: 1142–1151. Abstract Airway …

There is a lack of high-quality evidence on what treatment should be used in children with
properly characterised severe, therapy-resistant asthma. Data have to be largely …